Compare BNY & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNY | CRBU |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.0M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | BNY | CRBU |
|---|---|---|
| Price | $10.22 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 52.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.60 | $0.66 |
| 52 Week High | $10.80 | $3.54 |
| Indicator | BNY | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 45.15 |
| Support Level | $10.13 | $1.75 |
| Resistance Level | $10.20 | $1.97 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 67.37 | 66.20 |
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.